Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA" (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is… Read more
Tonix Pharmaceuticals Holding Corp (TNXP) - Total Assets
Latest total assets as of September 2025: $252.44 Million USD
Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) holds total assets worth $252.44 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tonix Pharmaceuticals Holding Corp - Total Assets Trend (2008–2024)
This chart illustrates how Tonix Pharmaceuticals Holding Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tonix Pharmaceuticals Holding Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Tonix Pharmaceuticals Holding Corp's total assets of $252.44 Million consist of 73.1% current assets and 26.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.6% |
| Accounts Receivable | $7.90 Million | 4.9% |
| Inventory | $8.41 Million | 5.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $120.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Tonix Pharmaceuticals Holding Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tonix Pharmaceuticals Holding Corp's current assets represent 73.1% of total assets in 2024, a decrease from 100.0% in 2008.
- Cash Position: Cash and equivalents constituted 60.6% of total assets in 2024, down from 88.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 5.2% of total assets.
Tonix Pharmaceuticals Holding Corp Competitors by Total Assets
Key competitors of Tonix Pharmaceuticals Holding Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Tonix Pharmaceuticals Holding Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tonix Pharmaceuticals Holding Corp generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tonix Pharmaceuticals Holding Corp is currently not profitable relative to its asset base.
Tonix Pharmaceuticals Holding Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.89 | 3.33 | 8.96 |
| Quick Ratio | 9.62 | 2.81 | 9.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $187.04 Million | $ 35.36 Million | $ 78.17 Million |
Tonix Pharmaceuticals Holding Corp - Advanced Valuation Insights
This section examines the relationship between Tonix Pharmaceuticals Holding Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 1.08 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | $162.89 Million |
| Market Capitalization | $176.11 Million USD |
Valuation Analysis
Above Book Valuation: The market values Tonix Pharmaceuticals Holding Corp's assets above their book value (1.08 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Tonix Pharmaceuticals Holding Corp's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tonix Pharmaceuticals Holding Corp (2008–2024)
The table below shows the annual total assets of Tonix Pharmaceuticals Holding Corp from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $162.89 Million | +5.46% |
| 2023-12-31 | $154.46 Million | -31.56% |
| 2022-12-31 | $225.69 Million | -6.31% |
| 2021-12-31 | $240.90 Million | +145.36% |
| 2020-12-31 | $98.18 Million | +574.43% |
| 2019-12-31 | $14.56 Million | -44.69% |
| 2018-12-31 | $26.32 Million | -1.63% |
| 2017-12-31 | $26.75 Million | -2.75% |
| 2016-12-31 | $27.51 Million | -41.49% |
| 2015-12-31 | $47.02 Million | +18.91% |
| 2014-12-31 | $39.54 Million | +352.63% |
| 2013-12-31 | $8.74 Million | +312.62% |
| 2012-12-31 | $2.12 Million | +397.64% |
| 2011-12-31 | $425.45K | +9100.82% |
| 2010-12-31 | $4.62K | -64.52% |
| 2009-12-31 | $13.03K | -71.62% |
| 2008-12-31 | $45.91K | -- |